HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.

Abstract
There has been interest in generating T cells expressing chimeric artificial receptors (CARs) targeting CD19/CD20 antigens to treat B-cell lymphomas. If successful, however, this approach would likely impair humoral immunity because T cells may persist long-term. Most low-grade lymphoma and chronic lymphocytic leukemia (B-CLL) cells express monoclonal immunoglobulins carrying either kappa or lambda light chains. We, therefore, explored whether T lymphocytes could be genetically modified to target the tumor-associated light chain, sparing B lymphocytes expressing the reciprocal light chain, and consequently reduce impairment of humoral immunity. We found that T lymphocytes expressing the anti-kappa light chain CAR showed cytotoxic activity against Igkappa(+) tumor cell lines and B-CLL cells both in vitro and in vivo. We also found that the incorporation of the CD28 endodomain within the CAR enhanced the in vitro and in vivo expansion of transgenic T cells after tumor-associated antigen stimulation. Free Igkappa(+) did not compromise the ability of redirected T lymphocytes to eliminate Igkappa(+) tumors because these free immunoglobulins served to sustain proliferation of CAR-CD28 transgenic T cells. Thus, adoptive transfer of T lymphocytes targeting the appropriate light chain could be a useful immunotherapy approach to treat B-lymphocyte malignancies that clonally express immunoglobulin without entirely compromising humoral immunity.
AuthorsJuan Vera, Barbara Savoldo, Stephane Vigouroux, Ettore Biagi, Martin Pule, Claudia Rossig, Jessie Wu, Helen E Heslop, Cliona M Rooney, Malcolm K Brenner, Gianpietro Dotti
JournalBlood (Blood) Vol. 108 Issue 12 Pg. 3890-7 (Dec 01 2006) ISSN: 0006-4971 [Print] United States
PMID16926291 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Chemical References
  • Antigens, CD19
  • Antigens, CD20
  • CD28 Antigens
  • Immunoglobulin kappa-Chains
  • Immunoglobulin lambda-Chains
  • Neoplasm Proteins
  • Recombinant Fusion Proteins
Topics
  • Adoptive Transfer (methods)
  • Animals
  • Antibody Formation (immunology)
  • Antigens, CD19 (genetics, immunology)
  • Antigens, CD20 (genetics, immunology)
  • CD28 Antigens (genetics, immunology)
  • Cell Proliferation
  • Gene Expression Regulation, Leukemic (immunology)
  • Humans
  • Immunoglobulin kappa-Chains (immunology)
  • Immunoglobulin lambda-Chains (immunology)
  • K562 Cells
  • Lymphoma, B-Cell (genetics, immunology, therapy)
  • Mice
  • Mice, SCID
  • Neoplasm Proteins (immunology)
  • Protein Structure, Tertiary (genetics)
  • Recombinant Fusion Proteins (genetics, immunology)
  • T-Lymphocytes, Cytotoxic (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: